# US 2026/0219272 A1 · Method and device for predicting significant gastric aspiration and lung transplant outcome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0219272 A1
- Document ID: US20260219272A1
- Status: Published application
- Kind: A1
- Application number: 19/182,347
- Filed: 2023-10-18
- Published: 2026-07-30
- Earliest claimed: 2022-10-18
- Assignees: University Health Network
- Applicants: University Health Network
- Inventors: Shafique KESHAVJEE; Marcelo CYPEL; Tereza MARTINU; Andrew SAGE; Rayoun RAMENDRA
- Web page: https://patentgrep.com/patent/US20260219272A1

## CPC

- G01N 33/573: for enzymes or isoenzymes
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/54388: {based on lateral flow}
- G01N 2333/96416: Aspartic endopeptidases (3.4.23)
- G01N 2333/96477: Pepsin (3.4.23.1; 3.4.23.2; 3.4.23.3)
- G01N 2800/12: Pulmonary diseases
- G01N 2800/245: Transplantation related diseases, e.g. graft versus host disease
- G01N 2800/382: Cystic fibrosis
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods, kits and devices for detecting pepsinogen A4 (PGA4), and optionally bile acid (BA), in lungs such as transplant recipient lungs for assessing gastric aspiration and/or likelihood of developing an adverse outcome for the recipient are described. Methods involve obtaining from the lung a lung-derived fluid sample (LDFS); detecting in the sample the level, or presence or absence of PGA4, and optionally BA; and identifying the lung as i) likely to have gastric aspiration when PGA4 is present in LDFS, or the PGA4 level is greater than its cut-off in LDFS, and optionally when the level of the BA is greater than the BA cut-off level in LDFS, or ii) unlikely to have gastric aspiration when PGA4 is absent in LDFS, or the PGA4 level is equal or less than the PGA4 cut-off level in LDFS, and optionally when the BA level is equal or less than its cut-off in LDFS.

## Claims

### Claim 1

A method of assessing gastric aspiration in a lung, optionally a donor lung or a transplanted lung of a lung transplant recipient, the method comprising:
a) obtaining a lung-derived fluid sample from the lung such as a lung from a subject with cystic fibrosis, emphysema, or pulmonary fibrosis or the donor lung or the transplanted lung;
b) detecting a level, or the presence or absence, of pepsinogen A4 in the lung-derived fluid sample, and optionally detecting a level of a bile acid in the lung-derived fluid sample;
c) identifying the lung as i) likely to have gastric aspiration when pepsinogen A4 is present in the lung-derived fluid sample, or the level of pepsinogen A4 is greater than the pepsinogen A4 cut-off level in the lung-derived fluid sample, and optionally when the level of the bile acid is greater than the bile acid cut-off level in the lung-derived fluid sample, or ii) unlikely to have gastric aspiration when pepsinogen A4 is absent in the lung-derived fluid sample, or the level of pepsinogen A4 is equal or less than the pepsinogen A4 cut-off level in the lung-derived fluid sample, and optionally when the level of the bile acid is equal or less than the bile acid cut-off level in the lung-derived fluid sample, or optionally iii) identifying the subject as having or likely to develop aspiration pneumonia, or having or likely to develop complications associated with gastric aspiration in the subject with cystic fibrosis, emphysema, or pulmonary fibrosis;
optionally wherein the bile acid cut-off level is determined by calculating in a population of donor lungs an average bile acid cut-off level above which at least 90% of the donor lungs were identified as having gastric aspiration;
d) optionally,
i) when pepsinogen A4 is present in the lung-derived fluid sample from the transplanted lung, or the level of pepsinogen A4 is greater than the pepsinogen A4 cut-off level in the lung-derived fluid sample from the transplanted lung, and optionally when the level of the bile acid in the lung-derived fluid sample from the transplanted lung is greater than the bile acid cut-off level, the method described herein further comprises treating the lung to reduce the likelihood of aspiration damage;
ii) when pepsinogen A4 is present in the lung-derived fluid sample from the donor lung, or the level of pepsinogen A4 is greater than the pepsinogen A4 cut-off level in the lung-derived fluid sample from the donor lung, and optionally when the level of the bile acid in the lung-derived fluid sample from the donor lung is greater than the bile acid cut-off level, the method described herein further comprises treating the donor lung to reduce the likelihood of aspiration damage;
iii) when pepsinogen A4 is present in the lung-derived fluid sample from the donor lung, or the level of pepsinogen A4 from the lung-derived fluid sample from the donor lung is greater than the pepsinogen A4 cut-off level, and optionally when the level of the bile acid in the lung-derived fluid sample from the donor lung is greater than the bile acid cut-off level, the method described herein further comprises performing EVLP on the donor lung to confirm lung function prior to transplantation;
iv) when pepsinogen A4 is present in the lung-derived fluid sample from the donor lung, or the level of pepsinogen A4 from the lung-derived fluid sample from the donor lung is greater than the pepsinogen A4 cut-off level, and optionally when the level of the bile acid in the lung-derived fluid sample from the donor lung is greater than the bile acid cut-off level, the method described herein further comprises treating the donor lung with surfactant;
v) when pepsinogen A4 is present in the lung-derived fluid sample from the donor lung, or the level of pepsinogen A4 from the lung-derived fluid sample from the donor lung is greater than the pepsinogen A4 cut-off level, and optionally when the level of the bile acid in the lung-derived fluid sample from the donor lung is greater than the bile acid cut-off level, the method described herein further comprises declining the donor lung for transplantation; or
vi) when pepsinogen A4 is present in the lung-derived fluid sample from the lung, or the level of pepsinogen A4 from the lung-derived fluid sample from the subject lung is greater than the pepsinogen A4 cut-off level, and optionally when the level of the bile acid in the lung-derived fluid sample from the subject lung is greater than the bile acid cut-off level, the method described further comprises treating the subject with complications associated with gastric aspiration.

### Claim 2 (depends on 1)

The method of claim 1, wherein the lung-derived fluid sample is a bronchoalveolar lavage (BAL) sample, a bronchial wash sample, an exhaled breath condensate sample, or an ex vivo lung perfusion (EVLP) perfusate sample.

### Claim 3 (depends on 2)

The method of claim 2, wherein the bronchial wash sample is large airway bronchial wash (LABW) sample.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, comprising detecting the level of a bile acid in the lung-derived fluid sample, wherein the bile acid is total bile acid (TBA) or a component thereof optionally selected from taurocholic acid (TCA), glycocholic acid (GCA) and cholic acid (CA).

### Claim 5 (depends on 4)

The method of claim 4, wherein the bile acid is TBA.

### Claim 6 (depends on 3)

The method of claim 3, wherein dilution correction of the LABW sample is standardized by the amount of total protein, albumin, or urea.

### Claim 7 (depends on 3)

The method of claim 3, wherein the pepsinogen A4 cut-off level is about 0.3 ng/uL and a level of the pepsinogen A4 greater than the cut-off level is indicative the donor lung or transplanted lung is likely to have significant aspiration, and a level of pepsinogen A4 equal to or less than the cut-off level is indicative the donor lung or transplanted lung is unlikely to have significant aspiration, and wherein the cut-off level is calculated by instilling and suctioning 20 mL of normal saline.

### Claim 8 (depends on 5)

The method of claim 5, wherein the bile acid cut-off level is about 1245 nM and a level of the TBA greater than the cut-off level is indicative the donor lung as likely to have significant aspiration and a level of TBA equal to or less than the cut-off level is indicative the donor lung is unlikely to have had significant aspiration, and wherein the cut-off level is calculated by instilling and suctioning 20 mL of normal saline.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1 to 8, wherein the method is carried out at point-of-care.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1 to 9, wherein the level or the presence or absence, of pepsinogen A4, and optionally the level of the bile acid, is detected by an immunoassay.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1 to 9, wherein the level or the presence or absence, of pepsinogen A4, and optionally the level of the bile acid, is detected by one or more of a Luminex® based assay, an enzyme-linked immunosorbent assay (ELISA), immunofluorescence, a radioimmunoassay, dot blotting, FACS, a protein microarray, immunoprecipitation followed by SDS-PAGE, immunocytochemistry, a simple Plex assay, a multiplex assay, mass spectrometry, an electrochemical assay, an enzymatic assay, a colorimetric assay, and any combination thereof.

### Claim 12

A method of assessing the likelihood of developing an adverse outcome in a lung transplant recipient, the method comprising:
a) obtaining a lung-derived fluid sample from a donor lung or a transplanted lung from the lung transplant recipient;
b) detecting a level, or the presence or absence, of pepsinogen A4 in the lung-derived fluid sample, and optionally detecting a level of a bile acid in the lung-derived fluid sample;
c) identifying the lung transplant recipient as i) likely to develop the adverse outcome when pepsinogen A4 is present in the lung-derived fluid sample, or the level of pepsinogen A4 is greater than the pepsinogen A4 cut-off level in the lung-derived fluid sample, and optionally when the level of the bile acid is greater than the bile acid cut-off level in the lung-derived fluid, or ii) unlikely to develop the adverse outcome when pepsinogen A4 is absent in the lung-derived fluid sample, or the level of pepsinogen A4 is equal or less than the pepsinogen A4 cut-off level in the lung-derived fluid sample, and optionally when the level of the bile acid is equal or less than the bile acid cut-off level in the lung-derived fluid sample,
optionally wherein the bile acid cut-off level is determined by calculating in a population of donor lungs an average bile acid cut-off level above which at least 90% of the donor lungs were identified as having gastric aspiration; and
d) optionally,
i) when pepsinogen A4 is present in the lung-derived fluid sample from the transplanted lung, or the level of pepsinogen A4 is greater than the pepsinogen A4 cut-off level in the lung-derived fluid sample from the transplanted lung, and optionally when the level of the bile acid in the lung-derived fluid sample from the transplanted lung is greater than the bile acid cut-off level, the method further comprises treating the lung transplant recipient to prevent the adverse outcome;
ii) when pepsinogen A4 is present in the lung-derived fluid sample from the donor lung, or the level of pepsinogen A4 is greater than the pepsinogen A4 cut-off level in the lung-derived fluid sample from the donor lung, and optionally when the level of the bile acid in the lung-derived fluid sample from the donor lung is greater than the bile acid cut-off level, the method further comprises treating the lung transplant recipient to prevent the adverse outcome;
iii) when pepsinogen A4 is present in the lung-derived fluid sample from the donor lung, or the level of pepsinogen A4 is greater than the pepsinogen A4 cut-off level in the lung-derived fluid sample from the donor lung, and optionally when the level of the bile acid in the lung-derived fluid sample from the donor lung is greater than the bile acid cut-off level, the method further comprises treating the donor lung with surfactant to prevent the adverse outcome; or
iv) when pepsinogen A4 is present in the lung-derived fluid sample from the donor lung, or the level of pepsinogen A4 is greater than the pepsinogen A4 cut-off level in the lung-derived fluid sample from the donor lung, and optionally when the level of the bile acid in the lung-derived fluid sample from the donor lung is greater than the bile acid cut-off level, the method further comprises declining the donor lung for transplantation.

### Claim 13 (depends on 12)

The method of claim 12, wherein the adverse outcome is gastroesophageal reflux disease (GERD), chronic lung allograft dysfunction (CLAD), or death.

### Claim 14 (depends on 13)

The method of claim 13, wherein the recipient identified as likely to develop the adverse outcome of GERD is selected for anti-reflux surgery or medical reflux medications.

### Claim 15 (depends on 13)

The method of claim 13, wherein the anti-reflux surgery is Nissen fundoplication or Toupet fundoplication.

### Claim 16 (depends on 13)

The method of claim 13, wherein the recipient identified as likely to develop the adverse outcome of CLAD or death is selected for retransplant.

### Claim 17 (depends on 16)

The method of claim 16, wherein the retransplanted recipient is assessed for the likelihood of developing an adverse outcome.

### Claim 18 (depends on 12, 13, 14, 15, 16, 17)

The method of any one of claims 12 to 17, wherein the lung-derived fluid sample is a bronchoalveolar lavage (BAL) sample, a bronchial wash sample, an exhaled breath condensate sample, or an ex vivo lung perfusion (EVLP) perfusate sample.

### Claim 19 (depends on 12, 13, 14, 15, 16, 17)

The method of any one of claims 12 to 17, wherein the lung-derived fluid sample is a large airway bronchial wash (LABW) sample.

### Claim 20 (depends on 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 12 to 19, comprising detecting the level of a bile acid in the lung-derived fluid sample, wherein the bile acid is total bile acid (TBA) or a component thereof optionally selected from taurocholic acid (TCA), glycocholic acid (GCA) and cholic acid (CA).

### Claim 21 (depends on 20)

The method of claim 20, wherein the bile acid is TBA.

### Claim 22 (depends on 19)

The method of claim 19, wherein dilution correction of the LABW sample is standardized by the amount of total protein, albumin, or urea.

### Claim 23 (depends on 19)

The method of claim 19, wherein the pepsinogen A4 cut-off level is about 0.3 ng/uL and a level of the pepsinogen A4 greater than the cut-off level is indicative the donor lung or transplanted lung is likely to have significant aspiration, and a level of pepsinogen A4 equal to or less than the cut-off level is indicative the donor lung or transplanted lung is unlikely to have significant aspiration, and wherein the cut-off level is calculated by instilling and suctioning 20 mL of normal saline.

### Claim 24 (depends on 21)

The method of claim 21, wherein the bile acid cut-off level is about 1245 nM and a level of the TBA greater than the cut-off level is indicative the donor lung as likely to have significant aspiration and a level of TBA equal to or less than the cut-off level is indicative the donor lung is unlikely to have had significant aspiration, and wherein the cut-off level is calculated by instilling and suctioning 20 mL of normal saline.

### Claim 25 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 12 to 24, wherein the method of assessing is carried out at point-of-care.

### Claim 26 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 12 to 25, wherein the level, or the presence or absence, of pepsinogen A4, and optionally the level of the bile acid, is detected by an immunoassay.

### Claim 27 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 12 to 25, wherein the level, or the presence or absence, of pepsinogen A4, and optionally the level of the bile acid, is detected by one or more of a Luminex® based assay, an enzyme-linked immunosorbent assay (ELISA), immunofluorescence, a radioimmunoassay, dot blotting, FACS, a protein microarray, immunoprecipitation followed by SDS-PAGE, immunocytochemistry, a simple Plex assay, a multiplex assay, mass spectrometry, an electrochemical assay, an enzymatic assay, a colorimetric assay, and any combination thereof.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A kit comprising one or more detection agents specific for pepsinogen A4, and optionally one or more detection agents specific for the level of the bile acid, and instruction for use, the kit optionally further comprising one or more of a microtiter plate, an assay buffer, a wash buffer, a sample diluent, a standard diluent, a detection agent diluent, streptavidin-PE, a filter plate, a sealing tape, at least one standard, and any combination thereof, optionally for performing the method of any one of claims 1 to 10, and 12 to 26.

### Claim 29

A point-of-care (POC) device for detecting the level, or presence or absence, of pepsinogen A4, and optionally for detecting the level of a bile acid, in a sample, comprising:
a housing;
a porous medium comprised in the housing, the porous medium comprising at a first end a sample portion and at a second end a testing portion;
a channel defined between the sample portion and the testing portion, the channel defining a flow path along which the sample passes and is drawn from the sample portion to the testing portion by capillary action; and
one or more reagents or detection agents for pepsinogen A4, and optionally one or more reagents or detection agents for bile acid, optionally in fluid communication with the testing portion or immobilized on the testing portion, the one or more reagents or detection agents being capable of reacting with the pepsinogen A4 to generate a detection signal, and optionally one or more reagents or detection agents for bile acid, optionally a visible color change or a fluorescent signal.

### Claim 30 (depends on 29)

The device of claim 29, comprising a plurality of flow paths through which the sample passes and which distributes the sample to a plurality of testing zones within the testing portion.

### Claim 31 (depends on 29)

The device of claim 29, wherein each of the testing zones comprises a different reagent or detection agent.

### Claim 32 (depends on 29, 30, 31)

The device of any one of claims 29 to 31, wherein the level, or the presence or absence, of pepsinogen A4, and optionally the level of the bile acid, is detected by an immunoassay.

### Claim 33 (depends on 29, 30, 31)

The device of any one of claims 29 to 31, wherein the level, or the presence or absence, of pepsinogen A4, and optionally the level of the bile acid, is detected by an immunoassay, comprising one or more of an enzyme-linked immunosorbent assay (ELISA), a multiplex assay, an electrochemical assay, an enzymatic assay, a colorimetric assay, and any combination thereof.

### Claim 34 (depends on 29, 30, 31, 32, 33)

The device of any one of claims 29 to 33, wherein the device is a lateral flow device.

### Claim 35 (depends on 29, 30, 31, 32, 33, 34)

The device of any one of claims 29 to 34, wherein the fluorescent signal is detected by a reader.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 29, 30, 31, 32, 33, 34)

The device of any one of claims 29 to 34 for carrying out a method for any one of claims 1 to 27.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 29, 30, 31, 32, 33, 34, 35, 36)

Use of the device of any one of claims 29 to 36 for performing the method of assessing of any one of claims 1 to 27.

### Claim 38

A method of assessing gastric aspiration of a subject comprising:
a) obtaining a lung-derived fluid sample;
b) detecting a level, or the presence or absence, of pepsinogen A4 in the lung-derived fluid sample, and optionally detecting a level of a bile acid in the lung-derived fluid sample;
c) identifying a lung as i) likely to have gastric aspiration when pepsinogen A4 is present in the lung-derived fluid sample, or the level of pepsinogen A4 is greater than a pepsinogen A4 cut-off level in the lung-derived fluid sample, and optionally when the level of the bile acid is greater than a bile acid cut-off level in the lung-derived fluid sample, or ii) unlikely to have gastric aspiration when pepsinogen A4 is absent in the lung-derived fluid sample, or the level of pepsinogen A4 is equal or less than a pepsinogen A4 cut-off level in the lung-derived fluid sample, and optionally when the level of the bile acid is equal or less than a bile acid cut-off level in the lung-derived fluid sample, or optionally iii) identifying the subject as having or likely to develop aspiration pneumonia, or having or likely to develop complications associated with gastric aspiration in a subject with cystic fibrosis, emphysema, or pulmonary fibrosis;
optionally wherein the bile acid cut-off level is determined by calculating in a population of healthy lungs an average bile acid cut-off level above which at least 90% of the lungs were identified as having gastric aspiration.
